## **Special Issue**

# Advances in the Pathogenesis of Hematopoietic Neoplasms

## Message from the Guest Editors

Hematologic neoplasms are classified, in the fifth edition of the WHO classification and the international consensus classification, using diagnostic criteria based on clinicopathological, morphologic,

immunophenotypic, molecular, and cytogenetic features. The major categories of hematopoietic neoplasms include myeloproliferative neoplasms, myelodysplastic syndromes,

myeloproliferative/myelodysplastic neoplasms, acute myeloid leukemia, B cell neoplasms, T cell neoplasms, histiocytic/dendritic cell neoplasms, and stromalderived neoplasms of lymphoid tissues. In recent years, major advances have been made in our understanding of these neoplasms fueled by advances in genomics and proteomics such as single-cell sequencing and spatial biology. In this Special Issue, we aim to review our current understanding of the major categories of hemopoietic neoplasms, focusing on advances in molecular pathogenesis and implications for diagnosis and therapy.

## **Guest Editors**

Dr. Raju K. Pillai

Department of Pathology, City of Hope National Medical Center, Duarte, CA 91010, USA

Dr. Steven T. Rosen

Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, City of Hope National Medical Center, Duarte, CA, USA

## Deadline for manuscript submissions

31 December 2025



## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/212858

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

#### **Author Benefits**

## **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

